homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

March 24, 2020

Silverback Therapeutics

Seattle-based private biopharmaceutical company Silverback Therapeutics raised $78.5 million in Series B funding and brought on Dr. Jonathan Root and Dr. Thilo Schroeder as board members. U.S. Venture Partners led the financing round, with participation from Nextech Invest, Hunt Investment Group, Pontifax Venture Capital, Colt Ventures, NS Investment, OrbiMed Advisors, Bristol-Meyers Squibb and Alexandria Venture Investments. Root is a general partner at U.S. Venture Partners and Schroeder is a partner at Nextech. Silverback is developing ways to eradicate solid tumors.




Email or user name:
Password:
 
Forgot password? Click here.